Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KRYS - Krystal Biotech, Inc.

IEX Last Trade
158.46
-24.180   -15.259%

Share volume: 0
Last Updated: Tue 24 Dec 2024 06:11:04 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$182.64
-24.18
-13.24%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
15%
Profitability 15%
Dept financing 2%
Liquidity 50%
Performance 10%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-3.83%
1 Month
-18.52%
3 Months
-11.70%
6 Months
-12.28%
1 Year
28.01%
2 Year
108.85%
Key data
Stock price
$158.46
P/E Ratio 
0.00
DAY RANGE
$162.28 - $182.64
EPS 
$0.00
52 WEEK RANGE
$112.34 - $219.34
52 WEEK CHANGE
$23.56
MARKET CAP 
5.606 B
YIELD 
N/A
SHARES OUTSTANDING 
28.730 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/04/2024
BETA 
1.16
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$374,936
AVERAGE 30 VOLUME 
$298,929
Company detail
CEO: Krish S. Krishnan
Region: US
Website: krystalbio.com
Employees: 210
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Krystal Biotech, Inc. engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105, KB301, KB407, KB104, KB5xx and KB3xx product.

Recent news